• Publications
  • Influence
Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction.
Coupling of automated ROI placement and PVEc provides a tool for integrated analysis of brain PET/MRI data, which allows a recovery of true GM ROI values, with a high degree of accuracy when R-PVEc or mMG-Pvec is used.
Diffusion‐weighted imaging in multiple system atrophy: A comparison between clinical subtypes
Multiple system atrophy can be classified into two main types, a Parkinsonian (MSA‐P) and a cerebellar (MSA‐C) variant based on clinical presentation. We obtained diffusion‐weighted magnetic
Brain atrophy and lesion load in a large population of patients with multiple sclerosis
Patients with multiple sclerosis have significant atrophy of both white matter (WM) and gray matter (GM), and GM atrophy is the most significant MRI variable in determining the final disability.
Prolonged impairment of regional contractile function after resolution of exercise-induced angina. Evidence of myocardial stunning in patients with coronary artery disease.
Findings indicate that myocardial stunning may ensue after effort angina in patients with severe coronary artery disease, as the functioning of previously ischemic segments normalized between 60 and 120 minutes of recovery.
Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization
To evaluate the effect of hyperprolactinaemia and its treatment with dopamine‐agonists on bone mass and turnover in adolescent patients compared to adults, a large number of patients were assigned to the H1N1 intensive care unit.
Hodgkin’s lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms
The authors' model–based study supports the use of advanced RT techniques to successfully spare OARs and to reduce the risk of radio-induced toxicities in HL patients, however, the estimated increase of SMNs’ risk inherent to TOMO and IMRT techniques should be carefully considered in the evaluation of a risk-adapted therapeutic strategy.
Sorafenib in advanced iodine‐refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG‐PET
The experience of off‐label use of the tyrosine kinase inhibitor sorafenib for treatment of advanced iodine‐refractory DTC is reported.